GSK and Janssen wade into competitive RA market with Phase III sirukumab program
This article was originally published in Scrip
GlaxoSmithKline and Janssen Biologics kicked off the Phase III program for their interleukin-6 (IL-6) inhibitor sirukumab (CNTO 136), which would compete with relative newcomers in the competitive rheumatoid arthritis market – Genentech's Actemra (tocilizumab), the first IL-6 inhibitor approved to treat patients with moderately to severely active rheumatoid arthritis, and Pfizer's novel oral Janus kinase (JAK) inhibitor tofacitinib.
You may also be interested in...
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug?